Which stocks are moving on Tuesday? Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Which stocks are experiencing notable movement on Tuesday? Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Get insights into the top gainers and losers of Tuesday's pre-market session. Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
These stocks are moving in today's after hours session Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trial The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.
Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday? Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia studies.
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program Artelo Biosciences advances its pipeline with ART26.12 for neuropathic pain and ART27.13 for cancer-related anorexia, targeting 2025 milestones.
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024 ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024 ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023 ARTL stock results show that Artelo Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
